#Incyte

[newshare24]

Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz ®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer

” Phase 3 POD1UM-304 trial met primary endpoint of overall survival (OS) and all secondary endpoints in patients with previously untreated metastatic non-small cell lung cancer (NSCLC) ” Data presented at the European Society for Medical (TASE:) Oncology (ESMO) Asia Congress 2024 support the planned 2025 filing of a supplemental Biologics License Application (sBLA) in the U.S. for retifanlimab in…

[pier-carlo-universe]

La Vitiligine Week arriva in Piemonte: incontri gratuiti con dermatologi per sensibilizzare e supportare i pazienti

Dal 25 al 30 novembre, Torino e Novara saranno tra le città protagoniste della Vitiligine Week, una campagna nazionale dedicata a chi convive con questa malattia cronica autoimmune.

Dal 25 al 30 novembre, Torino e Novara saranno tra le città protagoniste della Vitiligine Week, una campagna nazionale dedicata a chi convive con questa malattia cronica autoimmune. L’iniziativa, promossa da SIDeMaST e APIAFCO, offrirà incontri gratuiti con specialisti in dermatologia per migliorare la consapevolezza sulla vitiligine e presentare le ultime possibilità terapeutiche. Un’occasione…

[cleverthylacine]

I've been mainlining Westworld.

I love Dolores. I really do.

She's done horrible things but G-d forbid women do anything.

Also she would be such a fabulous Decepticon.

[dailyanarchistposts]

Biotechnology and the future of humanity

Animals Are Commodities Too

Under slavery human individuals are owned, are property. Under capitalism workers aren’t owned but they have to sell their labour/time/creativity because capitalists own everything (land, the means of production, transport and communication etc) that would enable people to live outside of wage labour and the market place. Now, instead of individuals owning non-human animals as part of their subsistence, corporations are claiming the right to ‘own’ whole species of animals. This process of patenting life can be traced back to the 1980 US Supreme Court ruling, which stated that a GM bacterium (modified to digest oil) could be patented. Not just that one bacterium of course but the whole, created species. In 1985 the US Patent and Trademark Office ruled that GM plants, seeds and plant tissues could be patented. Now the corporations can demand royalties and licence payments every time farmers use those plants or seeds. Monsanto holds a patent on (i.e. owns and rents out) all GM cotton and soya. Patents have been granted on biological characteristics of plants as well. For example, a patent has been issued to Sungene for a variety of sunflower that has a high oleic acid content. But the patent covers the characteristic as well as the genes that code for it, so any plant breeder who achieves the same result by traditional methods could be sued.

In 1987 animals joined the biotech market place when a Harvard biologist patented ‘oncomouse’, a GM organism (mouse) predisposed to develop cancer for use in medical ‘research’. By 1997 40 GM ‘species’ of animal had been patented, including turkey, nematodes, mice and rabbits. Hundreds of other patents are pending on pigs, cows, fish, sheep and monkeys among others. In 1976 a leukaemia patient named John Moore had his cancerous spleen removed under surgery at the University of California. Without his knowledge or consent some of the cells from his spleen were cultured and found to produce a protein which could be used in the manufacture of anti-cancer drugs. The estimated value of this cell-line to the pharmaceutical industry is $3 billion. In 1984 the California Supreme Court ruled that he was not entitled to any of these profits.

A US company called Biocyte holds a patent on (owns) all umbilical cord cells. Systemix Inc has a patent on (owns) all human bone marrow stem cells, these being the progenitors of all cells in the blood. The worldwide market for cell lines and tissue cultures was estimated to be worth $426.7 million to the corporations in 1996. Not only cells but also fragments of DNA can be patented (owned) in this way. Incyte, for example, has applied for patents on 1.2 million fragments of human DNA. The logic of this is that ‘genes for’ particular diseases such as cystic fibrosis, diabetes, various cancers etc could become the property of pharmaceutical companies who could then make huge profits on tests for such genes and genebased therapies. There is no space here to get into a lengthy criticism of the reductionist idea that individual genes simply map onto well-defined physical traits underlying the whole theory and practice of GM. It’s enough to say that research into patenting (owning), for example, a supposed’ breast cancer gene’ is of little benefit to humanity if it is true, as some scientists have estimated, that 90% of breast cancers are unrelated to genetics but are triggered by environmental pollution, diet and lifestyle factors. So what’s new? Capitalism, indeed class-society in general, always seizes the living and turns it into profit and power, declares ownership where previously there was only life: from the enclosure of the commons to the seizing of millions of human beings from Africa to be slaves to the current looting of tropical biodiversity for use in the biotech labs.

[metastatblog]

Atopic Dermatitis Market Analysis, Size, Share, Growth, Trends, and Forecasts by 2031

The Global Atopic Dermatitis market represents a dynamic landscape where the healthcare industry intersects with the pursuit of effective solutions for a chronic and inflammatory skin condition affecting millions worldwide. Atopic Dermatitis, commonly known as eczema, is characterized by red, itchy rashes that often manifest during childhood and persist into adulthood.

𝐆𝐞𝐭 𝐚 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭:https://www.metastatinsight.com/request-sample/2536

Companies

AbbVie Inc.

Incyte Corporation

Leo Pharma, Inc.

Otsuka Pharmaceuticals Co., Ltd.

Pfizer Inc.

Regeneron Pharmaceuticals, Inc.

Sanofi S.A.

Viatris, Inc.

Arcutis Biotherapeutics, Inc.

Asana Biosciences, Inc.

Bayer AG

Bristol-Myers Squibb Company

Dermavant Sciences, Inc.

Eli Lilly and Company

Galderma, Inc.

T𝐡𝐞 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭:@https://www.metastatinsight.com/report/atopic-dermatitis-market

As the demand for advanced therapeutic interventions continues to grow, the market for Atopic Dermatitis solutions has witnessed a significant surge in activity.

One of the defining features of the Global Atopic Dermatitis market is its adaptability to the ever-changing needs of patients and healthcare professionals alike. With a focus on providing relief from the relentless symptoms of Atopic Dermatitis, the market has become a vibrant hub for research, innovation, and collaboration among pharmaceutical companies, biotech firms, and medical researchers. This environment has catalyzed the development of novel treatment modalities, ranging from topical creams to cutting-edge biologic therapies.

As stakeholders navigate this expansive market, they encounter challenges and opportunities shaped by factors such as regulatory landscapes, patient preferences, and advancements in medical science. Regulatory bodies play a pivotal role in shaping the trajectory of the Global Atopic Dermatitis market, ensuring that new therapies meet stringent safety and efficacy standards. Simultaneously, the market responds to the evolving preferences of patients, who increasingly seek personalized and convenient treatment options.

In pharmaceuticals, the market showcases a diverse array of products aimed at managing Atopic Dermatitis symptoms. Topical corticosteroids, calcineurin inhibitors, and phosphodiesterase-4 inhibitors stand as pillars of traditional treatments, while the advent of biologics like dupilumab has introduced a new era of precision medicine. These innovations not only provide relief but also underscore the market's commitment to addressing the root causes of Atopic Dermatitis, promising long-term management for patients.

The Global Atopic Dermatitis market is not only a hub for pharmaceutical advancements but also a fertile ground for technological integration. Digital health solutions, ranging from telemedicine platforms to mobile applications, are gaining traction in facilitating remote patient monitoring and enhancing the overall patient experience. This infusion of technology improves healthcare accessibility and empowers individuals to actively participate in managing their Atopic Dermatitis.

The Global Atopic Dermatitis market emerges as a dynamic and responsive arena, where scientific innovation meets the pressing needs of those grappling with a chronic skin condition. As the market continues to evolve, propelled by research breakthroughs and technological integration, it holds the promise of transforming the landscape of Atopic Dermatitis management, ushering in an era of personalized, effective, and patient-centric care.

Global Atopic Dermatitis market is estimated to reach $38668.6 Million by 2031; growing at a CAGR of 16.3% from 2024 to 2031.

Contact Us:   

inquiry@metastatinsight.com

+1 214 613 5758

[digicloudm]

Incyte Stock Sinks as Sales Forecast for Key Drugs Falls Short

Piotr Swat / SOPA Images / LightRocket via Getty Images Shares of Incyte slumped Monday after the drugmaker’s fourth-quarter adjusted profit and 2025 sales forecasts missed analysts’ expectations. The company’s sales topped estimates for the fourth quarter as its two biggest drugs, Jakafi and Opzelura, grew year-over-year. Despite the strong latest quarter for the two drugs, Incyte’s projections…

[memotrends]

The Stock Incedte sinks as a forecast of sales for key drugs not

Piotr Swat / Sopa Images / Lighthrocket via Getty Images Incyte’s actions collapsed on Monday after the profit appropriate to the fourth quarter of the fourth quarter and the 2025 sales forecasts missed the expectations of analysts. The company’s sales have passed the estimates for the fourth quarter since its two largest drugs, Jakafi and Optzelura, have grown from year to year. Despite the…

[third-new]

Incyte stock sinks as the sales preview for key drugs is scarce

Piotr Swat / Sopa Images / Lightrocket via Getty Images Shares of Incyte fell on Monday after the fourth quarter of the drug maker adapted profits and 2025 sales prospects that failed the expectations of analysts. The company's sales were at the top of estimates for the fourth quarter as its two largest drugs, Jakafi and Opzelura, grew year on year. Despite the strong latest quarter for both…

[newtras]

Incyte stock sinks as the sales preview for key drugs is scarce

Piotr Swat / Sopa Images / Lightrocket via Getty Images Shares of Incyte fell on Monday after the fourth quarter of the drug maker adapted profits and 2025 sales prospects that failed the expectations of analysts. The company's sales were at the top of estimates for the fourth quarter as its two largest drugs, Jakafi and Opzelura, grew year on year. Despite the strong latest quarter for both…

[satrthere]

Incyte stock sinks as the sales preview for key drugs is scarce

Piotr Swat / Sopa Images / Lightrocket via Getty Images Shares of Incyte fell on Monday after the fourth quarter of the drug maker adapted profits and 2025 sales prospects that failed the expectations of analysts. The company's sales were at the top of estimates for the fourth quarter as its two largest drugs, Jakafi and Opzelura, grew year on year. Despite the strong latest quarter for both…

[kkumarsblog]

Neurofibromatosis Type 1 Market Growth, Key Players, and Future Outlook

Overview of the Neurofibromatosis Type 1 Market

Neurofibromatosis Type 1 (NF1) is a rare genetic condition that affects the nervous system, leading to tumor growth along nerves throughout the body. With an estimated prevalence of 1 in 3,000 individuals worldwide, NF1 is one of the most common single-gene disorders. Despite its rarity, the Neurofibromatosis Type 1 market is expanding due to increased awareness, advancements in research, and the development of novel treatment options.

Neurofibromatosis Type 1 Market Size and Key Growth Factors

The Neurofibromatosis Type 1 market size is anticipated to grow significantly over the next decade. Factors contributing to this expansion include rising diagnosis rates, increased investment in research and development (R&D), and the introduction of innovative therapies. Reports suggest that the market is valued at several hundred million dollars, with a projected CAGR in the coming years. The key drivers fueling this growth include:

Growing awareness and early detection

Advancements in targeted therapies and gene therapy

Government funding and support for rare disease research

Neurofibromatosis Type 1 Market Forecast and Emerging Trends

The Neurofibromatosis Type 1 market is expected to expand further due to several key factors:

Early Diagnosis and Improved Screening – Advanced diagnostic techniques are enabling timely detection and treatment.

Breakthrough Therapies – The introduction of MEK inhibitors has significantly improved treatment options for NF1 patients.

Robust R&D Investment – Leading pharmaceutical and biotechnology companies are actively conducting clinical trials to develop new drugs.

Regulatory Initiatives – Orphan drug designations and fast-track approvals are expediting the introduction of novel NF1 treatments.

Support from Advocacy Organizations – Groups like the Children’s Tumor Foundation and Neurofibromatosis Network are driving patient support and funding research initiatives.

Leading Neurofibromatosis Type 1 Companies

Several Neurofibromatosis Type 1 companies are at the forefront of drug development, including:

AstraZeneca

SpringWorks Therapeutics

Novartis

Roche

Pfizer

Array BioPharma

Incyte Corporation

Recursion Pharmaceuticals

BridgeBio Pharma

Genentech

These Neurofibromatosis Type 1 companies are focusing on expanding their NF1 treatment portfolios through R&D investments and strategic collaborations.

Advancements in the Neurofibromatosis Type 1 Drugs Market

The Neurofibromatosis Type 1 drugs market is evolving with innovative treatment strategies, such as:

MEK Inhibitors – Approved treatments like selumetinib have set new standards for NF1 therapy.

Gene Therapy & Precision Medicine – Scientists are working on gene-based treatments for NF1.

Combination Therapies – Multi-targeted treatment approaches are being explored.

Immunotherapy – Research is focusing on immune-based treatments for NF1-related tumors.

Challenges in the Neurofibromatosis Type 1 Drugs Market

Despite advancements, the Neurofibromatosis Type 1 drugs market faces hurdles such as:

High treatment costs

Limited availability of FDA-approved therapies

Variability in disease presentation among patients

Regulatory complexities in drug approval

Future Market Opportunities

The Neurofibromatosis Type 1 market forecast highlights key areas of growth, including:

Expansion of clinical trials and research funding

Increased global market reach

Identification of NF1 biomarkers for targeted treatments

Industry collaborations to drive innovation

Conclusion

The Neurofibromatosis Type 1 market is on a strong growth trajectory, fueled by ongoing research, increased awareness, and significant investments from leading Neurofibromatosis Type 1 companies. With an expanding therapeutic pipeline, the Neurofibromatosis Type 1 market size is expected to rise substantially in the coming years.

Top-Selling Reports by DelveInsight:

Athlete's Foot market | tuberculosis market | wound healing devices market | attention deficit hyperactivity disorder ADHD market | complex regional pain syndrome market | coronary microvascular dysfunction market | diabetes insipidus market | HDAC inhibitors market | healthcare competitive benchmarking | heart failure market | hyperphosphatemia market | immune checkpoints activators market | Japan healthcare outlook market | joint reconstruction devices market | mantle cell lymphoma market | methicillin-resistant Staphylococcus aureus market | mouth neoplasms market | myocardial infarction market | neuroendocrine tumor market share | nocturia market | obstructive sleep apnea market | phototherapies for psoriasis market | plaque modification devices market | polycystic ovarian syndrome market | primary mediastinal large B-cell lymphoma market | rosacea market | sarcopenia market | testicular neoplasm market | type 1 diabetes market | vascular access devices market

About DelveInsight:

DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries.

Contact:

Kanishk | Email: kkumar@delveinsight.com

[global-research-report]

Peptide Therapeutics: Market Dynamics, Challenges, and Emerging Trends

The global peptide therapeutics market size is expected to reach USD 66.41 billion by 2030, according to a new report by Grand View Research, Inc. It is expected to grow at a CAGR of 6.1% from 2024 to 2030. Increasing demand for efficient and rapid-acting therapeutics for the treatment of cancer and other lifestyle-associated disorders, which result in lesser adverse effects, is anticipated to propel market growth. The rising incidence of cancer calls for exploring and introducing other means of therapies and low-cost treatment alternatives is expected to drive the market. Moreover, the growing geriatric population is expected to widen the consumer base by triggering the incidence rate of target diseases such as cancer and diabetes, which is expected to drive the demand for peptide therapeutics.

As per the International Agency for Research on Cancer (GLOBOCAN 2020) report, there will be 19,292,789 new cancer cases diagnosed globally in 2020, with 9,958,133 cancer deaths. Furthermore, the five-year prevalence of cancer was projected to be 50,550,287 worldwide. The global number of new cases of cancer is projected to reach 28,887,940 by 2040. As a result, the higher incidence of cancers around the world is set to perform an important role in the development of peptide therapeutics over the forecast period. Besides that, increasing awareness among health care providers and patients about the negative effects of chemotherapy and/or radiation therapy is a primary factor influencing the increased emphasis on alternative therapeutics like peptide-based drugs.

Technological advancements in the peptide manufacturing process are driving the market during the forecast period. Manufacturers and suppliers are focusing on the adoption of novel technologies to manufacture efficient drug molecules with low time and capital investment. Improvement in purification and automation process and less generation of waste are additional factors contributing to the market growth. For instance, in March 2022, Amgen announced the official opening of its latest bio-manufacturing facility in Holly Springs, North Carolina. The facility, which is set to open in 2025, will help cope with the growth of Amgen's medicines, which treat serious diseases like cancer and heart disease.

The COVID-19 pandemic is anticipated to spur the spectrum of cancer care, which includes delayed diagnoses, therapeutic interventions, and the impeding of clinical trials focused on developing cost-effective therapeutics for cancer treatment, with peptide therapeutics for cancer treatment being no exception, as per a research article published in Nature Cancer, 2020. There have been 21 peptide drugs in therapies for the treatment of COVID-19 as of May 2020, such as 15 synthetic peptides for the therapies of acute respiratory distress syndrome (ARDS) as well as other respiratory illnesses induced by severe acute respiratory infection. However, current implementations of peptide therapeutics in oncological and metabolic disorders and other fields have been hampered by drug shortages, operational problems, and the slow progress of clinical trials involving non-COVID-19 therapeutics.

For instance, in May 2022, EVER Pharma announced that Bortezomib has received EU-wide approval for the treatment of individuals with symptomatic myeloma and mantle cell lymphoma1. In May 2022, The European Commission approved Novartis' Jakavi post-steroid therapy for acute and chronic graft-versus-host ailments. Jakavi will be the first JAK1/2 inhibitor widely available for patients in Europe with steroid-refractory graft-versus-host ailment. In September 2021, Nimble Therapeutics and Incyte entered into strategic collaborative research to discover additional new peptide therapies.

Peptide Therapeutics Market Report Highlights

By application, cancer held the second-largest revenue share in 2023 owing to the increasing demand for alternative therapeutics over conventional treatment options. Peptides are being used as potential therapeutic agents in cancer treatment

The generic type segment is expected to showcase an upward shift due to the patent expiration of blockbuster peptides and supportive government initiatives pertaining to the introduction of the generic class

Outsourcing manufacturing segment is anticipated to grow at the fastest CAGR during the forecast period owing to the requirements of complex procedures and a shift in preference toward outsourcing, which helps in eliminating the cost of production

By synthesis technology, hybrid technology is expected to witness the fastest growth over the forecast period. Benefits associated with this technology such as time conservation and ease of usage for both solid- and liquid-phase peptide synthesis are the key factors affirming growth

North America held the largest share in terms of revenue in 2023 owing to a higher level of awareness pertaining to genomics and proteomics products, well-established R&D infrastructure, and rising funding initiatives

Peptide Therapeutics Market Segmentation

Grand View Research has segmented the global peptide therapeutics market report based on application, type, type of manufacturer, route of administration, synthesis technology, and region

Peptide Therapeutics Application Outlook (Revenue, USD Billion, 2018 - 2030)

Cancer

Metabolic Disorders

Cardiovascular Disorders

Respiratory Disorders

Gastrointestinal Disorders

Infectious Diseases

Pain

Dermatological Disorders

Neurological Disorders

Renal Disorders

Others

Peptide Therapeutics Type Outlook (Revenue, USD Billion, 2018 - 2030)

Generic

Innovative

Peptide Therapeutics Type of Manufacturers Outlook (Revenue, USD Billion, 2018 - 2030)

In-house

Outsourced

Peptide Therapeutics Route of Administration Outlook (Revenue, USD Billion, 2018 - 2030)

Parenteral Route

Oral Route

Pulmonary

Mucosal

Others

Peptide Therapeutics Synthesis Technology Outlook (Revenue, USD Billion, 2018 - 2030)

Solid Phase Peptide Synthesis (SPPS)

Liquid Phase Peptide Synthesis (LPPS)

Hybrid Technology

Peptide Therapeutics Regional Outlook (Revenue, USD Billion, 2018 - 2030)

North America

US

Canada

Europe

UK

Germany

France

Spain

Italy

Denmark

Sweden

Norway

Asia Pacific

Japan

China

India

South Korea

Australia

South Korea

Latin America

Brazil

Mexico

Argentina

MEA

South Africa

UAE

Saudi Arabia

Kuwait

List of Key Players

Eli Lilly and Company

Pfizer Inc.

Amgen Inc.

Takeda Pharmaceutical Company Limited

AstraZeneca

Teva Pharmaceutical Industries Ltd.

Sanofi

Hoffmann-La Roche Ltd

Novartis AG

Novo Nordisk A/S

GlaxoSmithKline plc.

Ironwood Pharmaceuticals, Inc.

Radius Health, Inc.

Ipsen Pharma

Order a free sample PDF of the Peptide Therapeutics Market Intelligence Study, published by Grand View Research.

[pier-carlo-universe]

Torino: Arriva la "Vitiligine Week" in Campania e in tutta Italia, incontri gratuiti con i dermatologi per i pazienti

Dal 25 al 30 novembre, un’iniziativa nazionale promossa da SIDeMaST per sensibilizzare sulla vitiligine e offrire supporto specialistico gratuito.

Dal 25 al 30 novembre, un’iniziativa nazionale promossa da SIDeMaST per sensibilizzare sulla vitiligine e offrire supporto specialistico gratuito. Articolo Completo: Dal 25 al 30 novembre, l’Italia ospiterà la Vitiligine Week, una settimana dedicata a chi convive con la vitiligine, una malattia autoimmune che colpisce la pigmentazione della pelle. La campagna, organizzata dalla Società Italiana…

[biotech-news-feed]

The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its diversification plans. #BioTech #science

[leprivatebanker]

Incyte earnings beat by $0.04, revenue topped estimates

[djchorlocontrolection]

Entity - Heart Attack (Scratches Johnny One Move & Vocals MC Incyte) 2006